Morning Brief — July 30, 2026

Market Overview

Tech earnings are driving the tape today, with Microsoft’s massive beat (Azure topping $100B) lifting sentiment across the board and futures pointing ~0.7% higher. However, the backdrop is complicated: the 10-year yield is holding near 4.62%, rate hike odds for the upcoming Fed meeting are running ~1-in-3, and META’s weak revenue guidance is a reminder that even the best franchises can disappoint on the forward look. Today is a tale of two markets — earnings winners are flying while macro-sensitive names face headwinds from the bond market.

Claude’s Call

UP — MSFT’s “narrative-changing” quarter (Azure inflection, AI monetization confirmed) provides a strong gravitational pull for the entire growth complex, and the broad earnings backdrop leans positive enough to overcome rate jitter headwinds. The S&P 500 grinds higher today, led by software and healthcare, though gains are capped by rising yields and META’s hangover.

Top Movers

HURN (+40.4%) — $170.37 → $194.73 (+14.3% upside) Thesis: This is the real deal — a clean double-beat with revenue up 15.4% YoY, crushing consensus by $26M (4%), plus a full-year guidance raise. The AI-driven demand in digital services and managed healthcare consulting is a genuine secular tailwind, not a one-quarter fluke. Technically, HURN has blasted through its 6-month high of $172.37 and is approaching the Fib 1.272 extension at $194.73 — a legitimate near-term target, but the stock is extended on day one. RSI at 83.5 screams overbought; this is not a chase-at-the-open situation. Levels: Exit at Fib 1.272 extension $194.73. Support at Fib 23.6% retracement $152.97. Volume is concerning at only 0.08x avg — conviction is low despite the price move.

MKTX (+29.9%) — $163.29 → $172.85 (+5.9% upside) Thesis: Hard catalyst, binary event — ICE (NYSE parent) agreed to acquire MarketAxess for $6 billion, full stop. This is an M&A premium play, not a momentum trade. At $163.29, the stock is trading below the reported deal price neighborhood, suggesting either deal uncertainty or a cash/stock mix discount. RSI at 30.39 is surprisingly low for a +30% day, which hints this stock was deeply depressed pre-announcement (confirmed by the 34% six-month decline noted in prior coverage). This is now an arb trade, not a growth story. Levels: Exit at $172.85 (Fib 23.6% retracement = likely deal-price convergence zone). Support at $140.97 (Fib 61.8%) if deal falls through — that’s your worst-case floor.

MANH (+21.3%) — $204.02 → $226.63 (+11.1% upside) Thesis: Manhattan Associates is firing on all cylinders — record bookings, cloud revenue up 26%, full-year revenue guidance raised to $1.16-1.17B, and the launch of Sightline (explainable AI in supply chain planning) gives the AI narrative real product substance. This isn’t just riding the AI hype wave; MANH has actual enterprise software stickiness and expanding margins (GAAP operating margin guided 24.2-24.4%). The stock is at its 6-month high, and while the Fib 1.272 extension at $226.63 is achievable over the next week, today’s entry is chasing a 21% single-day pop. Levels: Exit at Fib 1.272 extension $226.63. Support at Fib 23.6% retracement $184.40 — that’s your stop zone on a pullback. RSI at 35.36 is oddly low; may reflect the stock’s depressed pre-earnings base.

MSFT (+13.7%) — $444.11 → $489.81 (+10.3% upside) Thesis: Azure crossing $100B in annualized revenue is the inflection point bulls have been waiting for — this confirms Microsoft is the picks-and-shovels winner of enterprise AI adoption, not just a promise. EPS of $16.68 is a monster print, and the narrative shift from “AI spending skepticism” to “AI monetization confirmed” is repricing the multiple right now. WSB is 80% bullish with 945 mentions — retail is piling in. Technically, at $444 the stock is below its 6-month high of $460.52 and sitting above the Fib 23.6% support at $435.11, giving it a reasonable base. RSI at 12.19 is extraordinarily low — this looks like a data anomaly or the stock was deeply washed out pre-earnings. Levels: Exit at Fib 1.272 extension $489.81. Support at Fib 38.2% retracement $419.38 — that’s your stop if the post-earnings euphoria fades quickly.

CORT (+21.2%) — $112.67 → $134.36 (+19.3% upside) Thesis: Corcept delivered a genuine upside shock — revenue beat by 18%, full-year guidance came in 15% above analyst estimates at $1.15B midpoint, and LIFYORLI (ovarian cancer) contributed $47.6M in its FIRST quarter on market. That’s a blockbuster launch velocity. The +1,000% EPS surprise headline is dramatic but reflects a low base; the real story is that two revenue drivers are now working simultaneously. At $112.67, this is the 6-month high — there’s no overhead resistance from prior trading, meaning price discovery is wide open. RSI at 50.0 despite a 21% move suggests healthy accumulation, not exhaustion. Levels: Exit at Fib 1.272 extension $134.36. Support at Fib 23.6% retracement $93.54 — a wide stop, reflecting the stock’s volatile nature.

GRMN (+16.2%) — $294.83 → $321.42 (+9.0% upside) Thesis: Garmin’s Q2 was a record quarter with revenue up 11% YoY to $2.02B and operating income surging 30% to $616M — the operating leverage story here is real. The full-year guide raised to ~$8.05B revenue with 27% operating margins is exceptional for a hardware-centric company. The premium aviation tech pivot (G2000 PRIME flight deck) adds a higher-margin, defensible moat product. GRMN is at its 6-month high, and the health/fitness secular trend continues to support wearables. This isn’t a meme — it’s a quality compounder having a breakout quarter. Levels: Exit at Fib 1.272 extension $321.42. Support at Fib 23.6% retracement $271.76 — solid floor on any pullback. SMA-50 at $241.11 is deep support.

CAKE (+13.6%) — $101.14 → $114.02 (+12.7% upside) Thesis: The Cheesecake Factory just crossed $1 billion in quarterly revenue for the first time, delivered same-store sales growth of 5.8% (well above the 2-3% consensus expected), and beat EPS by $0.26 (22%). In a challenged consumer environment, 5.8% SSS is genuinely impressive and suggests the brand is taking share from more casual competitors. RSI at 83.5 is overbought — same caveat as HURN — but the milestone revenue achievement and the SSS beat give this a fundamental anchor. The restaurant sector is getting a broader earnings-season lift (Chipotle also raised guidance). Levels: Exit at Fib 1.272 extension $114.02. Support at Fib 23.6% retracement $89.97. Volume at 0.04x avg is very thin — the move lacks conviction and could fade.

GEHC (+12.2%) — $71.90 → $90.91 (+26.4% upside) Thesis: GE HealthCare beat on both revenue ($5.3B) and EPS ($1.13 vs $1.04 expected), reported record backlog, and strong orders growth — this is a clean, broad-based beat. The AI-in-imaging and diagnostics theme is real and multi-year. At $71.90, GEHC is below its Fib 50% retracement at $71.82 — it’s in the support zone, not overextended. With a Fib 1.272 extension at $90.91, there’s meaningful upside from here. The Patient Care Solutions margin headwinds acknowledged on the call are a watch item, but the core imaging/diagnostics franchise is performing. Levels: Exit at Fib 1.272 extension $90.91. Support at Fib 61.8% retracement $68.90 and SMA-50 at $63.90.

BAX (+16.6%) — $28.87 → $33.02 (+14.4% upside) Thesis: Baxter is a turnaround story finally showing signs of life — the stock was cited as potentially 19% undervalued on cash flow pre-earnings, and today’s 16.5% move suggests the earnings print confirmed the thesis. This is a healthcare equipment name with a 5-year decline of ~65% that may be finding a bottom. At $28.87, it’s at its 6-month high, but the Fib 1.272 extension at $33.02 is still a reasonable target if the turnaround narrative holds. Tread carefully — this is a show-me story, not a momentum growth name. Levels: Exit at $33.02 (Fib 1.272). Support at Fib 23.6% retracement $26.14 and SMA-50 at $21.14.

Headlines to Watch

NYSE Owner ICE to Buy MarketAxess in $6 Billion Deal — A structural consolidation of fixed-income electronic trading; watch the arb spread on MKTX and assess spillover read-throughs to other fintech/exchange operators like CBOE and Tradeweb.
Microsoft Azure Tops $100B, Q4 Beat Lifts Most Price Targets — The single most important earnings print of the week; confirms AI monetization is real and will put pressure on analysts to re-rate the entire cloud/AI infrastructure complex upward.
Meta Issues Weak Revenue Guidance, Raises Capex Outlook — The bear case in one headline: META is spending more while guiding revenues lower, raising the specter that AI capex is consumption, not investment; watch for read-throughs to GOOGL and AMZN tonight.
US 30-Year Yield Near 2007 High, Fed Rate Hike Odds Rising — The macro wrecking ball that could derail today’s earnings-driven rally; any deterioration in long-end yields will disproportionately hit high-multiple growth names.
Corcept LIFYORLI Launch: $47.6M in First Quarter — One of the strongest drug launches in biotech this year; validates the oncology franchise and should trigger upward revisions across the specialty pharma coverage universe.
Garmin’s G2000 PRIME Aviation Tech Shift — A quietly important secular story: Garmin is moving from commodity GPS hardware to premium integrated flight systems; this is a margin mix shift with multi-year implications.
Wall Street Sends Warning as AI Tech Stocks Stumble After Earnings — The “buy the rumor, sell the news” dynamic is playing out in real-time; META’s selloff despite beating EPS is a cautionary tale that narrative and execution must now align.

Claude’s Top Picks

MSFT (+13.7% today, +16.4% week) — $444.11 → $489.81 (+10.3% upside) Valuation: No comps data provided, but at ~$444 post-beat with Azure at $100B+ annualized run rate, the forward multiple is more defensible than it’s been in 18 months — this is the market’s highest-quality AI monetization story. Upside: Azure inflection confirmed, narrative shift from “AI spending skepticism” to “AI paying off” will drive multiple re-rating over the next 1-2 weeks; analyst price target upgrades will provide sustained bid. Risk: Rising 30-year yields near 2007 highs are the knife at the throat of all high-multiple tech — if the bond market reprices aggressively post-Fed, MSFT gets sold regardless of fundamentals.

GEHC (+12.2% today, +17.2% week) — $71.90 → $90.91 (+26.4% upside) Valuation: No direct comps provided, but at ~$72 with record backlog and growing AI-imaging adoption, GEHC screens cheaply relative to the broader med-tech universe trading at premium multiples — this is the overlooked “picks and shovels” of AI in healthcare. Upside: Record order backlog provides revenue visibility, AI-enhanced imaging is a sticky, high-margin upgrade cycle, and the stock is trading right at Fib 50% support — the risk/reward is asymmetric from here. Risk: The Patient Care Solutions segment is margin-challenged and management flagged inflationary pressures; if that headwind accelerates, it offsets the imaging beat narrative.

CORT (+21.2% today, +16.6% week) — $112.67 → $134.36 (+19.3% upside) Valuation: Comps flag CORT as EXPENSIVE at 31x forward P/E vs peer median of 14.7x, but with an 18% revenue beat, 15% guidance raise above consensus, and a blockbuster first-quarter LIFYORLI launch, this is a case where the headline valuation understates the earning power revision cycle ahead. Upside: Two franchises now growing simultaneously (Cushing’s + ovarian cancer), full-year guidance well above street estimates means upward EPS revisions will continue for 2-3 quarters — the re-rate cycle is early. Risk: EXPENSIVE vs peers is not dismissible — if LIFYORLI growth disappoints in Q3 or the Cushing’s franchise shows any pricing pressure from generics, the premium multiple collapses fast.

GRMN (+16.2% today, +22.6% week) — $294.83 → $321.42 (+9.0% upside) Valuation: No specific comps provided, but Garmin’s 27% operating margin guidance at $8.05B revenue scale puts it in elite hardware/software hybrid territory — it deserves a premium multiple relative to pure hardware peers. Upside: The aviation tech upgrade cycle (G2000 PRIME) is a margin-accretive product shift, fitness wearables demand remains secular, and the full-year guidance raise has room for further upside given H1 outperformance. Risk: Volume at 0.05x average is thin — this is not a high-conviction institutional accumulation day, which means the move could give back 5-8% quickly if macro sentiment deteriorates.

NEO (+14.0% today, +9.0% week) — $15.27 → $17.47 (+14.4% upside) Valuation: No comps provided, but NeoGenomics trades at a significant discount to the broader molecular diagnostics universe given its historical losses — if EBITDA expansion continues, this is a re-rating candidate. Upside: 11% revenue growth with margin expansion and a full-year guidance raise is exactly the formula for a small-cap diagnostic name to re-rate; next-gen sequencing is a durable clinical tailwind and RSI at 20.49 suggests this was deeply oversold before the catalyst. Risk: The pharma services segment was flagged as challenged on the earnings call, and any macro-driven slowdown in biopharma clinical trial spending would directly hit NEO’s second revenue pillar.

Avoid

HURN — Already +40% on the day with RSI at 83.5 and volume at just 0.08x average, this is the definition of a low-conviction gap — you’re chasing a move that happened with almost no volume support and the stock is already approaching the Fib 1.272 extension at $194.73.

GENVR — No clear fundamental catalyst connecting to today’s +35% move (the news flow is about Gen Digital / GEN, not a company called GENVR), volume at 3.2x average in a sub-$3 stock is a classic pump signal, and the RSI at 50 with a 71% weekly gain is a textbook micro-cap trap.

BLKB — Blackbaud merely reaffirmed guidance (did not raise) and pointed to the “upper half” of prior ranges — that’s not a catalyst deserving a +17% move; at forward P/E of 7x vs peer median of 11.9x it’s cheap for a reason (3.3% revenue growth), and the RSI at 31.54 suggests the pre-move base was already technically broken.

WSB Sentiment Check

MSFT — WSB says: BULLISH (80% bullish) Claude says: AGREE — Azure at $100B, EPS of $16.68, and a “narrative-changing” quarter are exactly the kind of fundamental inflection points that justify retail euphoria; the technicals back it up with the stock below its 6-month high and above Fib 23.6% support — this bull case is real.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY — Micron is caught in a brutal technical no-man’s land: $800 current price vs SMA-50 at $960 and a 6-month high of $1,213, meaning it’s in a confirmed downtrend; the SK Hynix beat is a positive read-through for memory demand, but MU needs its own catalyst to break the trend — the mixed sentiment is actually the right read here.

META — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — META’s own guidance was the problem, not the execution, and “buy the dip on weak guidance” while capex is being raised is a dangerous bet; technically the stock is at its 6-month low of $533.93 with the SMA-50 at $602.80 far overhead — this is a falling knife and the 80% bullish WSB read is classic retail buying at the wrong part of the cycle.

SNDK — WSB says: BEARISH (30% bullish) Claude says: AGREE — SNDK at $1,176 vs a 20-day high of $1,915 and SMA-50 at $1,710 is technically destroyed; the 6-month high of $2,335 is a distant memory and the stock has lost half its value from peak — WSB’s bearish read is correct, this chart is broken and there’s no visible technical support until $1,217 (Fib 61.8%), which is still above current price suggesting more downside.

NVDA — WSB says: MIXED (55% bullish) Claude says: PARTIALLY — NVDA at $192 is below its SMA-50 of $206 and well below the 6-month high of $235, which is technically concerning; however, the MSFT Azure beat is a strong indirect positive (Azure runs on NVDA silicon), and if AI capex spend is being confirmed by hyperscalers, NVDA’s demand pipeline stays intact — the mixed sentiment is appropriate but I’d lean slightly more bullish than 55% given the MSFT catalyst today.

Earnings Scorecard

BE — REPORTED | Stock: +20.1% | EPS: $0.77 Reaction justified but incomplete: A 680% earnings surge (from a very low base) is dramatic, but the “speed-to-power” AI data center angle is the real catalyst here — Bloom Energy is positioning itself as a behind-the-meter power solution for AI compute facilities; the +20% is reasonable but the $286 analyst target suggests the market still undervalues the AI power theme — buy-the-dip on any pullback.

MSFT — REPORTED | Stock: +13.7% | EPS: $16.68 Reaction justified and likely insufficient: Azure crossing $100B in annualized revenue is a structural inflection, not a one-quarter beat; analyst targets average $555, implying 25% upside from current levels — the market’s +14% response is appropriate as a first move, but re-rating has further to go — hold and add on dips.

SKHY — REPORTED | Stock: +9.5% | EPS: $7.20 Reaction looks understated: SK Hynix benefiting from AI memory demand surge (read-through: HBM chips for NVDA/AMD GPUs) in an environment where Samsung’s chip profit jumped 250-fold — the +9.5% is conservative if the memory upcycle thesis holds; buy-the-dip with MU as the US proxy.

META — REPORTED | Stock: -8.5% | EPS: $27.11 Reaction justified: Weak revenue guidance + higher capex is the worst combination for a high-multiple ad-tech stock in a rising rate environment; the sell-off is rational and may have further to go — the stock is at 6-month lows with the SMA-50 overhead — sell-the-rip on any bounce toward $560-570.

GLW — REPORTED | Stock: +6.5% | EPS: $2.17 Reaction slightly understated: Corning’s AI data center fiber/optical interconnect exposure is a legitimate secular tailwind; however, the guidance “hit a wall” per one analyst, which caps upside — hold if you own it, don’t chase.

KLAC — REPORTED | Stock: +5.9% | EPS: $3.52 Reaction looks insufficient given the beat, but the context matters: KLA is having its “worst month ever” according to headlines, meaning this +6% is a dead-cat bounce within a broken downtrend; the beat couldn’t stop the broader semi-equipment selloff — hold, don’t add until the sector finds a floor.

CMG — REPORTED | Stock: +5.9% | EPS: $1.08 Reaction justified: Chipotle raised full-year sales outlook after beating Q2, confirming the consumer food-away-from-home trade is resilient despite macro pressure; +5.9% is proportional to a mid-size guidance raise — hold, read-through is positive for CAKE today.

APH — REPORTED | Stock: +5.7% | EPS: $4.00 Reaction justified: Record sales plus surging AI demand for Amphenol’s connectors and cable assemblies is a durable picks-and-shovels story — +5.7% on record results feels conservative; buy-the-dip as a lower-profile AI infrastructure beneficiary.

VRT — REPORTED | Stock: +5.6% | EPS: $4.42 Reaction counterintuitive: VRT “sinks” per headlines but the data shows +5.6% — this suggests the initial reaction was a sell-off on a revenue miss that was then partially recovered; with the CEO defending AI demand and one analyst citing 68% upside, the stock may be setting up a buy-the-dip if it stabilizes above recent lows.

CAR — REPORTED | Stock: -4.8% | EPS: -$18.02 Reaction justified and may be understated: A recall-driven cost hit producing a massive EPS miss in a cyclical business is exactly the kind of negative surprise that warrants a sell; the rental car market dynamics are shifting against traditional players — avoid, this is not a dip to buy.

CI — REPORTED | Stock: -4.4% | EPS: $23.60 Reaction overdone: Cigna beat estimates AND raised guidance, yet the stock fell 4.4% — this is a classic “sell the news” setup where the guidance raise wasn’t large enough to satisfy expectations; managed care names are facing regulatory headwinds that are weighing on the sector broadly — buy-the-dip, the fundamental case remains intact.

ORLY — REPORTED | Stock: -3.8% | EPS: $3.15 Reaction mildly overdone: O’Reilly beat on both revenue and EPS, yet sold off — this is sector rotation out of defensive auto-parts names as the earnings-season mood favors growth over value today; hold — no reason to sell a quality compounder on a beat.

QCOM — REPORTED | Stock: -3.8% | EPS: $8.75 Reaction justified: A 25% profit decline on higher costs with smartphone market slowdown is a genuine fundamental problem — the beat on revenue doesn’t offset the margin compression story; avoid until smartphone unit volumes recover.

MA — REPORTED | Stock: +2.7% | EPS: $17.29 Reaction understated: Mastercard beat on revenue with strong consumer spending and cross-border payment growth — the global travel recovery continues to be a durable tailwind; +2.7% on a clean beat with strong forward indicators is too modest; buy-the-dip as a high-quality compounder at a reasonable premium.

XOM — REPORTED | Stock: +2.4% | EPS: $5.94 Reaction proportional: ExxonMobil is a commodity-price-levered business — the modest reaction reflects stable oil prices rather than a positive surprise; hold unless you have a specific oil price catalyst thesis.